Calvez V

Publications (4)0 Total impact

• Source

  Available from: Aloustapha Issiaka Maiga

  Article: Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

  Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG
  Antimicrob Agents Chemother. 01/2010; Feb;54:728-33..
• Source

  Available from: Aloustapha Issiaka Maiga

  Article: Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

  Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG
  Antivir Ther. 01/2009; 14`:23-9..
• Source

  Available from: Aloustapha Issiaka Maiga

  Article: Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.

  Derache A, Maiga AI, Traore O, Akonde A, Cisse M, Jarrousse B, Koita V, Diarra B, Carcelain G, Barin F, Pizzocolo C, Pizarro L, Katlama C, Calvez V, Marcelin AG
  J Antimicrob Chemother. 01/2008; SEP:62:456-63.
• Source

  Available from: Aloustapha Issiaka Maiga

  Article: HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.

  Marcelin AG, Jarrousse B, Derache A, Ba M, Dakouo ML, Doumbia A, Haidara I, Maïga A, Carcelain G, Peytavin G, Katlama C, Calvez V
  AIDS. 01/2007; Nov 12:2341-3..